Genor Biopharma Holdings Limited (6998.HK)

HKD 1.66

(-5.68%)

EBITDA Summary of Genor Biopharma Holdings Limited

Genor Biopharma Holdings Limited's latest annual EBITDA in 2023 was -551 Million CNY , up 18.48% from previous year.
Genor Biopharma Holdings Limited's latest quarterly EBITDA in 2024 Q2 was -44.07 Million CNY , down 0.0% from previous quarter.
Genor Biopharma Holdings Limited reported an annual EBITDA of -675.88 Million CNY in 2022, up 17.52% from previous year.
Genor Biopharma Holdings Limited reported an annual EBITDA of -819.5 Million CNY in 2021, up 72.5% from previous year.
Genor Biopharma Holdings Limited reported a quarterly EBITDA of -44.07 Million CNY for 2024 Q1, up 69.38% from previous quarter.
Genor Biopharma Holdings Limited reported a quarterly EBITDA of -131.54 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Genor Biopharma Holdings Limited (2023 - 2018)

Historical Annual EBITDA of Genor Biopharma Holdings Limited (2023 - 2018)

Year	EBITDA	EBITDA Growth
2023	-551 Million CNY	18.48%
2022	-675.88 Million CNY	17.52%
2021	-819.5 Million CNY	72.5%
2020	-2.98 Billion CNY	-521.43%
2019	-480.91 Million CNY	-97.88%
2018	-243.85 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-44.07 Million CNY	0.0%
2024 Q1	-44.07 Million CNY	69.38%
2023 Q2	-131.54 Million CNY	0.0%
2023 Q4	-143.95 Million CNY	0.0%
2023 Q3	-143.95 Million CNY	-9.43%
2023 FY	- CNY	18.48%
2023 Q1	-131.54 Million CNY	21.13%
2022 Q3	-166.78 Million CNY	19.62%
2022 Q2	-207.49 Million CNY	0.0%
2022 Q1	-207.49 Million CNY	11.49%
2022 FY	- CNY	17.52%
2022 Q4	-166.78 Million CNY	0.0%
2021 Q1	-185.66 Million CNY	10.81%
2021 FY	- CNY	72.5%
2021 Q4	-234.43 Million CNY	0.0%
2021 Q3	-234.43 Million CNY	-26.27%
2021 Q2	-185.66 Million CNY	0.0%
2020 Q1	-130.91 Million CNY	0.0%
2020 Q4	-208.16 Million CNY	0.0%
2020 Q3	-208.16 Million CNY	46.07%
2020 Q2	-386 Million CNY	-194.86%
2020 FY	- CNY	-521.43%
2019 FY	- CNY	-97.88%
2019 Q1	-64.19 Million CNY	0.0%
2018 FY	- CNY	0.0%

Peer EBITDA Comparison of Genor Biopharma Holdings Limited

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	703.949%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	213.191%